Eurofins

The test is based on the company's GARD platform for measuring genetic biomarkers of immune reactions to predict chemical sensitivities.

The system combines sample preparation technology capable of amplifying tens of thousands of locations in the genome with next-generation sequencing.

Genoma, which is based in Italy, offers a wide range of specialty diagnostics services with an emphasis on noninvasive prenatal testing, as well as oncology tests. 

An OpenArray panel designed to simultaneously test for 17 viruses and 13 bacteria and protozoa was able to detect pathogens from human blood donor samples with an accuracy of about 95 percent.

The deal will close in July and will expand Eurofins' capabilities in areas including DNA sequencing and genetic testing. 

The deal is expected to expand Eurofin's clinical diagnostic footprint in Europe.

The lab was opened earlier this year as the company's central genomics lab in North America, offering various genomic services such as DNA sequencing.

The company is hoping to find a niche among customers who want the quality of high-throughput oligonucleotide synthesis but smaller order volumes.

Living DNA can break down the origins of a customer’s ancestry into 21 distinct regions within Britain alone, as well as across 80 different worldwide populations.

Pages

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.